In a new U.S. Court of Appeals for the Federal Circuit opinion, Regents of the University of Minnesota v. LGI Corporation, et al., the court held that states, including public universities, are not entitled to sovereign immunity from Inter Partes Review (IPR) proceedings filed at the United States Patent and Trademark Office (USPTO) to challenge an issued patent. Judge Dyk, writing for the court, provides a nice overview of the history of administrative challenges to issued patents as well as the process for filing and prosecuting an IPR. Notably, Judge Dyk points to the resource constraints of the USPTO in evaluating patentability and that the federal government is essentially drafting third parties through IPRs to test patentability. Judge Dyk discusses and relies upon the reasoning of Saint Regis Mohawk Tribe v. Mylan Pharmaceuticals Inc., 896 F.3d 1322 (Fed. Cir. 2018). In that case, the Federal Circuit refused to apply tribal sovereign immunity to IPRs. The court notes that it was unnecessary to reach the issue whether the University of Minnesota waived sovereign immunity for an IPR by filing a patent infringement suit concerning the IPR challenged patent. This decision puts U.S. public university generated and owned patents in the IPR crosshairs. Interestingly, it puts U.S. public university patents on the same footing as foreign university owned and generated U.S. patents for purposes of challenge through IPRs, thus, removing a potential advantage for U.S. public universities versus foreign universities in the United States.
"Where money issues meet IP rights". This weblog looks at financial issues for intellectual property rights: securitisation and collateral, IP valuation for acquisition and balance sheet purposes, tax and R&D breaks, film and product finance, calculating quantum of damages--anything that happens where IP meets money.
Showing posts with label sovereign immunity. Show all posts
Showing posts with label sovereign immunity. Show all posts
Tuesday, 18 June 2019
U.S. Court of Appeals for the Federal Circuit: Public Universities do not have Sovereign Immunity from Patent IPRs
In a new U.S. Court of Appeals for the Federal Circuit opinion, Regents of the University of Minnesota v. LGI Corporation, et al., the court held that states, including public universities, are not entitled to sovereign immunity from Inter Partes Review (IPR) proceedings filed at the United States Patent and Trademark Office (USPTO) to challenge an issued patent. Judge Dyk, writing for the court, provides a nice overview of the history of administrative challenges to issued patents as well as the process for filing and prosecuting an IPR. Notably, Judge Dyk points to the resource constraints of the USPTO in evaluating patentability and that the federal government is essentially drafting third parties through IPRs to test patentability. Judge Dyk discusses and relies upon the reasoning of Saint Regis Mohawk Tribe v. Mylan Pharmaceuticals Inc., 896 F.3d 1322 (Fed. Cir. 2018). In that case, the Federal Circuit refused to apply tribal sovereign immunity to IPRs. The court notes that it was unnecessary to reach the issue whether the University of Minnesota waived sovereign immunity for an IPR by filing a patent infringement suit concerning the IPR challenged patent. This decision puts U.S. public university generated and owned patents in the IPR crosshairs. Interestingly, it puts U.S. public university patents on the same footing as foreign university owned and generated U.S. patents for purposes of challenge through IPRs, thus, removing a potential advantage for U.S. public universities versus foreign universities in the United States.
Labels:
federal circuit,
inter partes review,
IPRs,
Judge Dyk,
patents,
sovereign immunity
Tuesday, 31 October 2017
Ending Soveriegn Immunity for Tribes from Inter Partes Review
U.S. Senator McCaskill has introduced a Bill that would
remove sovereign immunity as a defense against Inter Partes Review of patents
for Indian Tribes. The Bill is
refreshingly short. It states:
A BILL
To abrogate the
sovereign immunity of Indian tribes as a defense in inter partes review of
patents.
Be it enacted
by the Senate and House of Representatives of the United States of America in
Congress assembled,
SECTION 1. Abrogation of tribal immunity in
certain patent claims.
(a) Definition.—In
this section, the term “Indian tribe” has the meaning given the term in section
4 of the Indian Gaming Regulatory Act (25
U.S.C. 2703).
(b) Abrogation of
immunity for purposes of inter partes review.—Notwithstanding any other
provision of law, an Indian tribe may not assert sovereign immunity as a
defense in a review that is conducted under chapter
31 of title 35, United States Code.
As previously discussed, the Bill is directed at Allergen’s recent attempt to use sovereign
immunity of Indian Tribes to insulate patents from Inter Partes Review at the
PTO by transferring its patents to the tribe in exchange for cash. Notably, Judge Bryson (of the Federal Circuit), sitting at the trial court level, recently asked Allergen to
demonstrate that its transfer is not a “sham." Judge Bryson further found the Allergen patents to be obvious.
Labels:
allergen,
indian tribes,
inter partes review,
Judge William Bryson,
sovereign immunity,
tribal immunity
Wednesday, 13 September 2017
Gaming IP: Smart or Damaging the Entire System
Here is an interesting case of gaming the IP system. I believe this type of tactic hurts the IP system as whole even if we may disagree about the need for reforms.
The New York Times has an informative article titled, “How to
Protect a Drug Patent? Give It to a
Native American Tribe.” The article
describes how Allergen, the pharmaceutical company:
will pay the [Native American] tribe
$13.75 million. In exchange, the tribe will claim sovereign immunity as grounds
to dismiss a patent challenge through a unit of the United States Patent and
Trademark Office. The tribe will lease the patents back to Allergan, and will
receive $15 million in annual royalties as long as the patents remain valid.
As discussed in
the article, this is apparently a strategy to protect the patents from Inter
Partes Review Proceedings at the United States Patent and Trademark
Office. As discussed in other posts,
public universities have successfully claimed sovereign immunity under the 11th
amendment of the U.S. Constitution from IPR Proceedings. I doubt this strategy will last long. I can understand how Allergen may think this may play well with the public because Native American tribes will receive much needed funding, but really? This looks very bad. Of course, folks are going to start asking what that funding is being used for.
Labels:
delaying generics,
drug patents,
gaming ip,
gaming the system,
inter partes review,
IPRs,
native American tribe,
pharmaceutical patents,
sovereign immunity,
Technology Transfer,
universities
Subscribe to:
Posts (Atom)